Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥50%

Trial Profile

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥50%

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs Cemiplimab (Primary) ; Ipilimumab (Primary) ; Pembrolizumab
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EMPOWER-lung 2
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 26 Sep 2018 Trial design of this study presented at the 19th World Conference on Lung Cancer.
    • 16 Aug 2018 Planned End Date changed from 13 Jan 2023 to 28 Mar 2023.
    • 16 Aug 2018 Planned primary completion date changed from 22 Dec 2022 to 6 Mar 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top